Compare Keel Infrastructure Corp. Common Stock (KEEL) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keel Infrastructure Corp. Common Stock vs Organon & Co. Common Stock — how do they compare? Keel Infrastructure Corp. Common Stock trades at $2.41 (market cap $1.58B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 2.3× Keel Infrastructure Corp. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Keel Infrastructure Corp. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 3 Days and Organon & Co. Common Stock for 0 Days on average.
| KEEL | OGN | |
|---|---|---|
Market Cap | $1.58B | $3.61B |
Volume | 40,501,716 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $6.66 | $13.81 |
52-Week Low | $1.71 | $5.70 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $1.90B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KEEL trades at $2.87, down 2.71% on the day, reflecting a bearish technical trend amid weak financial performance. The company reported a net loss of $208.51M on $229.28M revenue in 2025, with negative profit margins and cash flow from operations. Despite this, analyst consensus is unanimously bullish with a $6.25 price target, citing progress in its HPC and AI data center strategy, including a recent partnership with PowerSecure for its Moses Lake campus.
The outlook hinges on successful execution of its data center pivot, offering significant upside if leasing targets are met, but high execution risk and persistent losses pose substantial threats to shareholder value. Liquidity remains supported by financing activities, yet profitability challenges and competitive pressures require careful monitoring.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
